Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01881737 · ClinicalTrials.gov registry record · Phase 2
A Study of Pregnenolone in the Treatment of Individuals With Autism
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01881737: Completed Phase 2 study, sponsored by Stanford University.
NCT01881737 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01881737, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will assess the tolerability and effectiveness of pregnenolone in the treatment of behavioral deficits in adults with autism. Pregnenolone is a naturally occurring hormone found in the body which has been shown to help with the function of nerve cells. It is also shown to modulate the activity of certain brain receptors implicated in autism. We hope to examine the tolerability of pregnenolone in adults with autism.
Interventions
- DRUG Pregnenolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01881737
The ClinicalTrials.gov registry entry for NCT01881737 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pregnenolone is the first listed.
NCT01881737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01881737 about?
NCT01881737 is a clinical study titled "A Study of Pregnenolone in the Treatment of Individuals With Autism". This study will assess the tolerability and effectiveness of pregnenolone in the treatment of behavioral deficits in adults with autism. Pregnenolone is a naturally occurring hormone found in the body which has been shown to help with the function of nerve cells. It is also shown to modulate the act...
What is the current status of trial NCT01881737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2011-07. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01881737?
The interventions under investigation include: Pregnenolone (DRUG).
Who is sponsoring clinical trial NCT01881737?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.